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recipients of 4-6/6 HLA match grafts when at least 1.7  105
CD34 cells/kg are infused. This association was based on the
CD34 counts assessed on thawed products. But the question to be
addressed is indeed whether we can predict the thawed CD34 cell
dose based on an analysis of the pre-freeze CD34 enumeration
and the reliability of a CD34 assessment using an associated
aliquot. Therefore, we evaluated ﬁfty duplicate cryopreserved CB
aliquots (1.5 ml cryovials) from CB units stored according to the
standard banking procedures at the Madrid CBB (MCBB). After
shipment using a transport liquid nitrogen container, the aliquots
were thawed and processed by the same protocol at both the UM
and MCBB. Total pre-freezing NC/ml was 8.21  3.36  106.
Post-thaw counts at UM (6.77  2.92  106) and Madrid (6.49 
3.0  106) indicated equivalent NC recoveries (83  13% and 79
 15%, respectively). Cell viability by trypan blue before freezing
was 90  8%. However, there was a large difference between the
post-thaw viabilities at the UM (52  10%) and MCBB (81 
11%), indicating this technique is far from normalization. Simi-
larly, different CFU-GM scoring criteria at the UM and MCBB
(counting all CFU-GM colonies made up of greater than 40 or 20
cells, respectively) gave a lower CFU-GM number at UM vs.
MCBB (7.6  5.6 vs. 20.3  13.6/50000 cells plated). Despite this
variable readout, a signiﬁcant correlation between these values (r
0.7) was probably related to the consistency of the method and the
same culture media used in this study. The CD34 frequencies
(analyzed according to the ISHAGE dual-platform protocol) were
also discrepant. While the post-thaw %CD34 was 0.98  0.66 at
the UM, it was 0.57  0.39 at the MCBB (with the pre-freeze
%CD34 being 0.35  0.22). Bland-Altman and Intraclass Corre-
lation tests displayed considerable lack of agreement and no con-
sistent bias was observed between post-thaw CD34 at UM and
either pre-freeze or post-thaw CD34 values at MCBB. Thus, the
CD34 cell analysis at the UM and MCBB could not be used
interchangeably. However, linear regression showed a signiﬁcant
relationship (p  0.001). The linear equations estimated for each
prediction model were: i) y  2.758x  0.03121 (post-thaw [pt]
UM from pre-freeze [pf] MCBB counts); ii) y 1.534x 0.111 (pt
UM from pt MCBB counts); and iii) y  1.684x  0.00567 (pt
MCBB from pf MCBB counts). The coefﬁcient of determination
(R2a) for each model was 0.85, 0.82 and 0.80 respectively. There-
fore, as high as 85% and 82% of the total variance of post-thaw
CD34 values at the UM was explained respectively by the varia-
tion in pre-freeze (ﬁrst model) or post-thaw (second model) CD34
values at the MCBB. Importantly, all but one of the observed
CD34 counts were above the lower 90% individual prediction
limits. In summary, regardless the variability of CD34 cell enu-
meration at the UM and MCBB, it is possible to foresee with a
conﬁdence of 95% the CD34 cell dose that would be infused to
CB transplantation patients at the UM, either from the pre-freeze
MCBB data or from the CD34 assessment using a cryopreserved
aliquot. Whereas this regression model is only valid between the
UM and MCBB, this approach could be widely applied to predict
the transplantation outcomes from CD34 data provided by all CB
banks. Finally, on examination of the ﬂow cytometry data ﬁles, the
CD34 enumeration discrepancy was seemingly due to differences
in the initial cell acquisition performed at the UM and MCBB.
This discrepancy could be minimized by adopting uniform oper-
ating procedures.
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STANDARDIZATION OF CFU ASSAYS
Clarke, E., Atkinson, E.A. StemCell Technologies Inc., Vancouver, BC,
Canada
The advantages of using cord blood derived cells for the treat-
ment of leukemia and other hematological malignancies are now
well recognized. A recent regulatory ruling has mandated that a
functional test (e.g. a colony forming cell (CFC) assay) evaluating
the proliferative potential of the cells within the product following
cell processing and freezing must be performed if the sample is to
be used for transplantation. This highlights the need for a stan-
dardized assay. Previously published data have reported signiﬁcant
variability in the quantiﬁcation of the hematopoietic progenitors
using the CFC assay. Originally, recognition and enumeration of
the colonies was believed to account for this variability, however
variation in CFC quantiﬁcation could also be caused by different
media formulations or technical errors in sample preparation, cell
counting and dilution. Two distinct proﬁciency testing programs
were designed to assess the contribution of these various parame-
ters to the variability. The preliminary program, with 54 partici-
pants within North America, sought to determine the variability in
the recognition and enumeration of CFC. This was achieved by
determining the coefﬁcient of variation (CV) for CFU-GM and
total CFC enumeration when sample preparation events were
controlled. The second program was global, and also assessed the
contribution of the cell preparation steps to the overall variability
of the CFC assay. Participants (n  134) were provided with
identical vials of frozen bone marrow cells and were instructed to
thaw, wash, count, assess viability and dilute the cells prior to their
addition to a standardized formulation of MethoCult™. Fourteen
days later, participants quantiﬁed myeloid and erythroid colonies
as in the original tests. The considerable increase in the CVs in this
second test conﬁrmed that sample preparation steps contribute
signiﬁcantly to the variability in this assay. Standardized protocols
for cell preparation and training will decrease this variability and
facilitate global applicability of data generated from various labo-
ratories.
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UNRELATED CORD BLOOD TRANSPLANTATION IN PEDIATRIC PA-
TIENTS WITH NON-MALIGNANT DISEASES
Kurtzberg, J., Martin, P.L., Carter, S.L., Kernan, N.A., Sahdev, I.,
Wall, D., Pietryga, D., Wagner, J.E. The COLBT Steering Committee
The COBLT or Cord Blood Transplantation Study was a multi-
institutional study sponsored by the National Heart Lung and
Blood Institute. It was comprised of a banking and transplantation
study. The banking study established 3 banks which employed
common standards for donor screening and recruitment and cord
blood collection, processing, testing, cryopreservation and storage.
Screening of 34,700 women yielded 24,200 eligible for the study
who were approached for consent to participate. Eighty-ﬁve per-
cent (20,710 women) were consented and 17,207 were collected,
47% of which were discarded for low cell count, infectious disease
or maternal history exclusion or problems with processing. Of
note, a lower percentage of African American donations were
eligible for banking because they tended to have lower cell counts
per unit volume. Approximately 9112 units were moved to long
term storage and available for transplantation. The transplantation
study employed common protocols for preparative regimens,
GvHD prophylaxis and supportive care. Uniform deﬁnitions of
engraftment, GvHD and toxicity scoring, graft failure, causes of
death and relapse were employed. Strata were developed for chil-
dren and adults with malignant and non-malignant conditions.
This report focuses on outcomes in 69 patients with inborn errors
of metabolism transplanted between August of 1999 and June of
2004. The median age of the patients was 1.8 years (range 0.1-11.7
years). There was a predominance of males (55%) and Caucasians
(74%). The patients were diagnosed with MPS syndromes (57%),
ALD (12%), MLD (6%), Krabbe Disease (23%) and Tay Sachs
Disease (4%). Only 25% of patients were CMV seropositive before
transplant. A signiﬁcant portion of the patients (35%) had poor
performance status deﬁned by a Lansky score 80%. The
COBLT banks provided 70% of the donor units used in the study.
The median total nucleated cell dose and CD34 cell dose selected
were 8.7  107/kg and 2.4  105/kg, respectively. HLA matching
was performed using molecular typing at an intermediate resolu-
tion for HLA Class I A and B and high resolution for DRB1. High
resolution matching was scored retrospectively. The majority of
patients received grafts mismatched at 1 (45%) or 2 (48%) HLA
loci. After high resolution typing, 23% of patient/donor pairs were
demoted to lesser matches. Patients were prepared for transplant
with busulfan (16 doses with ﬁrst dose pharmacokinetics targeting
a steady state of 600-900 ng/ml), cyclophosphamide 200 mg/kg
and equine ATG 90 mg/kg. GvHD prophylaxis was delivered with
methylprednisolone and cyclosporine. The cumulative incidence
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